Eagle Health Investments LP Acquires Shares of 884,121 Ultragenyx Pharmaceutical Inc. $RARE

Eagle Health Investments LP bought a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 884,121 shares of the biopharmaceutical company’s stock, valued at approximately $29,521,000. Ultragenyx Pharmaceutical comprises about 4.9% of Eagle Health Investments LP’s portfolio, making the stock its 9th largest position. Eagle Health Investments LP owned 0.90% of Ultragenyx Pharmaceutical as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently modified their holdings of RARE. BlackRock Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical in the second quarter valued at approximately $355,746,000. Vanguard Group Inc. lifted its holdings in Ultragenyx Pharmaceutical by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 10,263,815 shares of the biopharmaceutical company’s stock worth $236,068,000 after buying an additional 131,087 shares in the last quarter. State Street Corp lifted its holdings in Ultragenyx Pharmaceutical by 16.5% during the 4th quarter. State Street Corp now owns 4,303,046 shares of the biopharmaceutical company’s stock worth $98,970,000 after buying an additional 610,559 shares in the last quarter. Wellington Management Group LLP boosted its position in Ultragenyx Pharmaceutical by 26.6% in the 4th quarter. Wellington Management Group LLP now owns 2,461,910 shares of the biopharmaceutical company’s stock valued at $56,624,000 after buying an additional 516,781 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in Ultragenyx Pharmaceutical by 1,030.4% in the 1st quarter. Assenagon Asset Management S.A. now owns 2,257,671 shares of the biopharmaceutical company’s stock valued at $47,298,000 after buying an additional 2,057,951 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, EVP Karah Herdman Parschauer sold 1,899 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, June 15th. The shares were sold at an average price of $24.62, for a total transaction of $46,753.38. Following the transaction, the executive vice president directly owned 94,462 shares of the company’s stock, valued at $2,325,654.44. This trade represents a 1.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Howard Horn sold 4,653 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $23.77, for a total transaction of $110,601.81. Following the completion of the transaction, the chief financial officer directly owned 105,689 shares of the company’s stock, valued at $2,512,227.53. This trade represents a 4.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 8,552 shares of company stock valued at $207,455 over the last three months. 5.20% of the stock is currently owned by corporate insiders.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ:RARE opened at $26.24 on Thursday. The firm’s 50 day simple moving average is $28.52 and its 200 day simple moving average is $24.96. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $18.29 and a fifty-two week high of $39.89. The company has a market capitalization of $2.59 billion, a price-to-earnings ratio of -4.49 and a beta of 0.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The firm had revenue of $214.00 million during the quarter, compared to analysts’ expectations of $183.08 million. During the same quarter in the previous year, the company earned ($1.17) earnings per share. The business’s revenue for the quarter was up 28.5% on a year-over-year basis. Equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -4.12 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on RARE shares. Wells Fargo & Company dropped their target price on Ultragenyx Pharmaceutical from $47.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, August 5th. Wall Street Zen upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Barclays lowered their price objective on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating for the company in a research report on Wednesday, April 29th. Weiss Ratings upgraded shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 9th. Finally, Royal Bank Of Canada raised their target price on shares of Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Ultragenyx Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average price target of $57.82.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.